checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


Uncover the unmet needs in psoriasis and psoriatic arthritis

 

Gain insight into the prevalence of psoriatic arthritis, how it affects patients at a cellular level, and what PDE4 inhibition may mean for treatment

Unmet needs remain in treatment1

Patients who discontinued traditional oral therapies did so primarily due to concerns about efficacy, safety, and tolerability1

 

Results from the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey

The MAPP survey was an extensive look at the unmet needs in psoriasis and psoriatic arthritis, and how these diseases impact patients’ lives. 3426 patients across 7 countries, as well as 781 rheumatologists and dermatologists in North America, were interviewed, all managed by an academic steering committee of thought leaders in dermatology and rheumatology.1


dissatisfaction with traditional oral therapies for psoriatic arthritis

*

Subset of all patients surveyed. Overall, 24% of all patients said they had been prescribed a traditional oral medication for their disease (eg, cyclosporine, methotrexate, acitretin, or fumaric acid esters) at some point since their diagnosis; of these, 43% were receiving therapy and 57% had discontinued use.


consider oral otezla for patients with psoriatic arthritis

MAPP, Multinational Assessment of Psoriasis and Psoriatic Arthritis; PDE4, phosphodiesterase type 4; PsA, psoriatic arthritis.

References: 1. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881. 2. Data on file, Celgene Corporation. 3. Ianculescu I, Weisman M.H. The role of methotrexate in psoriatic arthritis: what is the evidence? Clin Exp Rheumatol. 2015;33(Suppl. 93):S94-S97. 4. Mease P. Methotrexate in Psoriatic Arthritis. Bulletin of the Hospital for Joint Diseases. 2013;71(Suppl 1):S41-5. 5. Mease PJ. Spondyloarthritis: is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol. 2012;8(5):251-252. 6. Orbai A, Weitz J, Siegel EL, et al. Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. J Rheumatol. 2014;41;2290-2294.


Select an e-mail client to share

close x